522 related articles for article (PubMed ID: 27009094)
1. HIV-1 Latency and Eradication: Past, Present and Future.
Datta PK; Kaminski R; Hu W; Pirrone V; Sullivan NT; Nonnemacher MR; Dampier W; Wigdahl B; Khalili K
Curr HIV Res; 2016; 14(5):431-441. PubMed ID: 27009094
[TBL] [Abstract][Full Text] [Related]
2. The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
Rezaei SD; Lu HK; Chang JJ; Rhodes A; Lewin SR; Cameron PU
J Virol; 2018 Jul; 92(13):. PubMed ID: 29643247
[TBL] [Abstract][Full Text] [Related]
3. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
4. Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure.
Siliciano JD; Siliciano RF
J Infect Dis; 2021 Feb; 223(12 Suppl 2):13-21. PubMed ID: 33586775
[TBL] [Abstract][Full Text] [Related]
5. RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency.
Méndez C; Ledger S; Petoumenos K; Ahlenstiel C; Kelleher AD
Retrovirology; 2018 Oct; 15(1):67. PubMed ID: 30286764
[TBL] [Abstract][Full Text] [Related]
6. Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs.
Sadowski I; Hashemi FB
Cell Mol Life Sci; 2019 Sep; 76(18):3583-3600. PubMed ID: 31129856
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies.
Khanal S; Schank M; El Gazzar M; Moorman JP; Yao ZQ
Cells; 2021 Feb; 10(2):. PubMed ID: 33672138
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of latently infected HIV-1 viral reservoirs and correction of aberrant alternative splicing in the LMNA gene via AMPK activation: Common mechanism of action linking HIV-1 latency and Hutchinson-Gilford progeria syndrome.
Finley J
Med Hypotheses; 2015 Sep; 85(3):320-32. PubMed ID: 26115946
[TBL] [Abstract][Full Text] [Related]
9. Irreversible Loss of HIV-1 Proviral Competence in Myeloid Cells upon Suppression of NF-κB Activity.
Peters RJ; Stevenson M
J Virol; 2022 Jun; 96(12):e0048422. PubMed ID: 35604217
[TBL] [Abstract][Full Text] [Related]
10. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of HIV-1 proviral latency.
Bisgrove D; Lewinski M; Bushman F; Verdin E
Expert Rev Anti Infect Ther; 2005 Oct; 3(5):805-14. PubMed ID: 16207172
[TBL] [Abstract][Full Text] [Related]
12. HIV Provirus Stably Reproduces Parental Latent and Induced Transcription Phenotypes Regardless of the Chromosomal Integration Site.
Hashemi FB; Barreto K; Bernhard W; Hashemi P; Lomness A; Sadowski I
J Virol; 2016 Jun; 90(11):5302-14. PubMed ID: 26984732
[TBL] [Abstract][Full Text] [Related]
13. Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir.
Wang Z; Simonetti FR; Siliciano RF; Laird GM
Retrovirology; 2018 Feb; 15(1):21. PubMed ID: 29433524
[TBL] [Abstract][Full Text] [Related]
14. Novel AIDS therapies based on gene editing.
Khalili K; White MK; Jacobson JM
Cell Mol Life Sci; 2017 Jul; 74(13):2439-2450. PubMed ID: 28210784
[TBL] [Abstract][Full Text] [Related]
15. Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption.
Wang X; Xu H
Viruses; 2021 Feb; 13(2):. PubMed ID: 33670027
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Cellular Proliferation on the HIV-1 Reservoir.
Virgilio MC; Collins KL
Viruses; 2020 Jan; 12(2):. PubMed ID: 31973022
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
18. The role of integration and clonal expansion in HIV infection: live long and prosper.
Anderson EM; Maldarelli F
Retrovirology; 2018 Oct; 15(1):71. PubMed ID: 30352600
[TBL] [Abstract][Full Text] [Related]
19. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
20. Assays to Measure Latency, Reservoirs, and Reactivation.
Siliciano JD; Siliciano RF
Curr Top Microbiol Immunol; 2018; 417():23-41. PubMed ID: 29071475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
